查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046373

急性胰臟炎市場－全球產業規模、佔有率、趨勢、機會、預測：按治療、診斷、最終用戶、地區和競爭格局分類，2021-2031年

Acute Pancreatitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Diagnosis, By End-User By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球急性胰臟炎市場預計將從 2025 年的 52.1 億美元成長到 2031 年的 72.3 億美元，複合年成長率為 5.61%。

急性胰臟炎是一種胰臟發炎性疾病，其特徵是突發性腹痛和消化酵素水平升高，通常需要住院接受支持性治療。市場成長的主要促進因素是膽結石和酒精消費量增加等風險因素的日益普遍，這些因素導致全球患者數量上升。根據國際胰臟學會 (IAP) 預測，到 2025 年，急性間質性胰臟炎將佔所有確診病例的約 80%，這表明對治療和管理的需求持續旺盛，同時也凸顯了全球範圍內對有效診斷和治療策略的迫切需求。然而，市場擴張的主要障礙是缺乏針對該疾病潛在發炎機制的已通過核准的特異性藥物療法。目前的治療主要依賴輸液和疼痛管理等支持性治療，但這些措施往往不足以阻止重症壞死性胰臟炎的進展。這種治療缺口，加上處理複雜併發症帶來的巨大經濟負擔，持續阻礙市場發展。

市場概覽
預測期 2027-2031
市場規模：2025年 52.1億美元
市場規模：2031年 72.3億美元
複合年成長率：2026-2031年 5.61%
成長最快的細分市場 靜脈輸液
最大的市場 北美洲

市場促進因素

由膽結石和酒精引起的胰臟炎發生率不斷上升，是全球急性胰臟炎市場擴張的主要促進因素，並直接導致全球患者住院率上升。飲食習慣的改變和肥胖率的上升正在增加膽結石的發生率，而膽結石與胰臟炎密切相關。美國國立衛生研究院 (NIH) 於 2025 年 5 月發表的一項研究《膽結石患者急性胰臟炎的盛行率及相關危險因子》顯示，37.6% 的膽結石患者隨後發展為急性胰臟炎。此外，生活方式的改變正在擴大高危險群。發表於 2025 年 5 月《醫學前沿》(Frontiers in Medicine) 的一篇題為《15-39 歲青年胰臟炎的全球疾病負擔》的論文報告稱，青年族群中胰臟炎的盛行率激增 42.9%，在研究期間達到 106 萬例以上。日益加重的疾病負擔凸顯了製定有效臨床管理策略的迫切需求。同時，新療法的研發正在蓬勃發展，透過解決標靶治療嚴重短缺的問題，正在改變市場格局。製藥公司正超越傳統的症狀治療，擴大將具有特定作用機制的生物製藥候選藥物推進到後期臨床試驗階段。 2025年8月，CalciMedica在其2025年第二季財報中宣布了一項重要進展，詳細闡述了其計劃最終確定Auxora（一種有望成為首個治療方法急性胰臟炎的突破性藥物）的III期主要臨床試驗方案。這種研發管線的加速推進吸引了大量投資，預示著精準醫療即將到來，預計將降低重症胰臟炎的高發生率。

市場挑戰

全球急性胰臟炎市場成長的主要障礙在於缺乏針對該疾病發炎路徑的已通過核准藥物療法。與其他許多發炎性疾病不同，急性胰臟炎的治療特異性依賴輸液和鎮痛等症狀治療，而其他疾病則主要依靠高價值生物製藥和定向小分子化合物來驅動收入。這種對低利潤、特異性干預措施的依賴嚴重限制了市場的價值潛力，因為目前尚無針對潛在病理生理機製或預防組織壞死的高價療法。因此，儘管患者群體龐大，但由於商機僅限於低成本的非處方藥，而非創新且受專利保護的藥物，該市場難以實現顯著的收入成長。治療環境的這種巨大缺口有效地阻礙了市場擴張，將經濟負擔從藥品銷售轉移到了醫院服務。根據美國胃腸病學會的數據，2024年約有20%的急性胰臟炎患者會發展為中度或重度，並出現器官衰竭和壞死等併發症。這項統計數據凸顯了目前大量患者缺乏有效藥物治療來阻止疾病進展。由於醫療機構缺乏針對這些重症病例的緩解疾病藥物（DMT），潛在的盈利市場仍未開發，導致其市場估值與臨床負擔相比嚴重偏低。

市場趨勢

人工智慧 (AI) 與預測診斷的融合正在從根本上改變全球急性胰臟炎市場的臨床決策，彌補了傳統評分系統固有的準確性不足。臨床醫生擴大採用機器學習演算法，這些演算法能夠分析連續變量，從而比靜態指標更準確地預測疾病嚴重程度。 2025 年 3 月發表於 EMJ Reviews 的報導「AI 模型比傳統報導更準確地預測急性胰臟炎死亡率」重點介紹了這項技術進步。文章指出，基於 XGBoost 的新模型實現了 0.89 的曲線下面積(AUC)，顯著優於傳統的預後工具。這些創新透過臨床決策支援軟體的普及應用，提升了市場價值，使醫療專業人員能夠最佳化重症監護資源的分配。同時，市場正經歷著向微創內視鏡介入治療的重大轉變，尤其是「階梯式」治療方案，優先採用導管引流和內視鏡壞死組織切除，而非開放性手術清創。推動這一轉變的原因是需要降低治療腸壁壞死所需的侵入性手術帶來的高發生率。 2025年8月發表於Springer Nature的一項研究「感染性壞死性胰臟炎的階梯式治療方案」支持了這種不斷發展的治療方法的臨床有效性，該研究報告稱，階梯式治療策略使80.5%的病例實現了感染控制。這一趨勢正在積極重塑醫療設備的採購模式，推動了對管腔吻合金屬支架和專用內視鏡附件的需求成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球急性胰臟炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型進行治療（輸液療法、營養支持、鎮痛藥、內視鏡逆行性造影（ERCP）、其他治療）
    • 診斷（影像檢查、臨床檢查）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美急性胰臟炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲急性胰臟炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區急性胰臟炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲急性胰臟炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲急性胰臟炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球急性胰臟炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • SCM Lifescience
  • GNT Pharma Co
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • General Electric Company
  • Medtronic Plc
  • Boston Scientific Corporation
  • Fresenius Kabi USA
  • McNeil Consumer Healthcare
  • Sun BioPharma

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17335

The Global Acute Pancreatitis Market is projected to expand from USD 5.21 Billion in 2025 to USD 7.23 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.61%. Acute pancreatitis, an inflammatory condition of the pancreas, is characterized by sudden abdominal pain and elevated digestive enzymes, frequently requiring hospital admission for supportive care. Market growth is primarily fueled by the increasing prevalence of risk factors such as gallstones and rising alcohol consumption, which contribute to a growing global patient population. In 2025, acute interstitial pancreatitis constituted approximately 80% of all diagnosed cases, according to the International Association of Pancreatology, signifying a consistent and high demand for therapeutic management and highlighting the crucial need for effective diagnostic and treatment strategies worldwide. Yet, a significant barrier to market expansion is the absence of approved, specific pharmacological treatments that target the disease's underlying inflammatory mechanisms. Current care primarily involves supportive measures like fluid resuscitation and pain management, which often prove inadequate in halting the progression of severe necrotizing pancreatitis. This therapeutic void, compounded by the considerable economic burden associated with managing complex complications, continues to impede broader market development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.21 Billion
Market Size 2031USD 7.23 Billion
CAGR 2026-20315.61%
Fastest Growing SegmentIntravenous Fluids
Largest MarketNorth America

Market Driver

The increasing prevalence of gallstone-induced and alcohol-related pancreatitis is a primary catalyst fueling the expansion of the Global Acute Pancreatitis Market, directly contributing to higher patient admission rates globally. Shifts in dietary habits and rising obesity levels have led to an increased incidence of cholelithiasis, which is strongly linked to pancreatic inflammation. A study from the National Institutes of Health in May 2025, 'Prevalence and Associated Risk Factors of Acute Pancreatitis in Patients With Gallstones', indicated that 37.6% of patients diagnosed with gallstones subsequently developed acute pancreatitis. Furthermore, evolving lifestyle patterns are broadening demographic susceptibility, with a *Frontiers in Medicine* article from May 2025, 'Global burden of pancreatitis among individuals aged 15-39 years', reporting a 42.9% surge in pancreatitis prevalence among young adults, reaching over 1.06 million cases during the study period. This escalating disease burden underscores an urgent demand for effective clinical management strategies. Simultaneously, a surge in research and development for novel therapeutics is transforming the market landscape by addressing the critical deficiency in targeted treatment options. Pharmaceutical companies are increasingly moving beyond conventional supportive care to advance mechanism-specific biologic candidates through late-stage clinical trials. A notable development reported by CalciMedica in August 2025, in their 'Second Quarter 2025 Financial Results', detailed plans to finalize the design of a pivotal Phase 3 trial for Auxora, a potential first-in-class therapy for acute pancreatitis. This acceleration in pipeline activity attracts substantial investment and signals an imminent shift towards precision medicine, promising to reduce the high morbidity rates associated with severe forms of the condition.

Market Challenge

The principal obstacle hindering the growth of the Global Acute Pancreatitis Market is the notable absence of approved pharmacological therapies designed to specifically target the disease's inflammatory pathways. Unlike many other inflammatory conditions where high-value biologics or targeted small molecules drive revenue, acute pancreatitis management predominantly relies on generic supportive care such as intravenous fluids and analgesics. This reliance on low-margin, non-specific interventions severely curtails the market's value potential, as there are no premium-priced therapeutics available to address the underlying pathophysiology or prevent tissue necrosis. Consequently, the market struggles to achieve significant revenue growth despite a high patient volume, as financial opportunities are confined to low-cost commodities rather than innovative, patent-protected drugs. This pervasive gap in the treatment landscape effectively stagnates market expansion by transferring the economic burden towards hospital services rather than pharmaceutical sales. According to the American College of Gastroenterology, approximately 20% of patients diagnosed with acute pancreatitis in 2024 progressed to moderate or severe stages, characterized by complications such as organ failure or necrosis. This statistic highlights a substantial patient segment that currently lacks effective pharmaceutical intervention to halt disease progression. As healthcare providers lack disease-modifying pharmaceutical tools for these severe cases, the potential for a lucrative therapeutic market segment remains unfulfilled, keeping the overall market valuation disproportionately low relative to the clinical burden.

Market Trends

The integration of Artificial Intelligence for Predictive Diagnostics is fundamentally reshaping clinical decision-making within the Global Acute Pancreatitis Market by addressing the precision limitations inherent in traditional scoring systems. Clinicians are increasingly adopting machine learning algorithms capable of analyzing continuous variables to predict disease severity with greater accuracy compared to static metrics. This technological advancement was underscored by an EMJ Reviews article in March 2025, 'AI Model Predicts Acute Pancreatitis Mortality Better Than Traditional Methods', which reported that a novel XGBoost-based model achieved an Area Under the Curve (AUC) of 0.89, significantly outperforming conventional prognostic tools. Such innovations contribute to market value through the adoption of clinical decision support software, enabling healthcare providers to optimize the allocation of intensive care resources. Concurrently, the market is witnessing a decisive shift towards Minimally Invasive Endoscopic Interventions, particularly the "step-up" approach, which favors catheter drainage and endoscopic necrosectomy over open surgical debridement. This transition is motivated by the imperative to reduce the high morbidity associated with invasive procedures used to treat infected walled-off necrosis. The clinical efficacy of this evolving method was substantiated by a Springer Nature study in August 2025, 'Step-up approach for the treatment of infected necrotising pancreatitis', which reported that the step-up strategy successfully resolved infection in 80.5% of cases. This trend actively redefines medical device procurement, fostering increased demand for lumen-apposing metal stents and specialized endoscopic accessories.

Key Market Players

  • SCM Lifescience
  • GNT Pharma Co
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • General Electric Company
  • Medtronic Plc
  • Boston Scientific Corporation
  • Fresenius Kabi USA
  • McNeil Consumer Healthcare
  • Sun BioPharma

Report Scope

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Pancreatitis Market, By Treatment

  • Intravenous Fluid
  • Nutritional Support
  • Analgesics
  • Endoscopic Retrograde Cholangiopancreatography (ERCP)
  • Other treatments

Acute Pancreatitis Market, By Diagnosis

  • Imaging tests
  • Laboratory Tests

Acute Pancreatitis Market, By End-User

  • Hospitals & Clinics
  • Ambulatory care Centers
  • Others

Acute Pancreatitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Pancreatitis Market.

Available Customizations:

Global Acute Pancreatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Pancreatitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments)
    • 5.2.2. By Diagnosis (Imaging tests, Laboratory Tests)
    • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Acute Pancreatitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Diagnosis
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Pancreatitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Diagnosis
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Acute Pancreatitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Diagnosis
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Acute Pancreatitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Diagnosis
        • 6.3.3.2.3. By End-User

7. Europe Acute Pancreatitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Diagnosis
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Pancreatitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Acute Pancreatitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Acute Pancreatitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Acute Pancreatitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Diagnosis
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Acute Pancreatitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Diagnosis
        • 7.3.5.2.3. By End-User

8. Asia Pacific Acute Pancreatitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Diagnosis
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Acute Pancreatitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Acute Pancreatitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Acute Pancreatitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Acute Pancreatitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Acute Pancreatitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Acute Pancreatitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Diagnosis
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Acute Pancreatitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Acute Pancreatitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Acute Pancreatitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By End-User

10. South America Acute Pancreatitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Diagnosis
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Acute Pancreatitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Acute Pancreatitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Acute Pancreatitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Acute Pancreatitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. SCM Lifescience
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GNT Pharma Co
  • 15.3. Baxter International Inc.
  • 15.4. B. Braun Melsungen AG
  • 15.5. General Electric Company
  • 15.6. Medtronic Plc
  • 15.7. Boston Scientific Corporation
  • 15.8. Fresenius Kabi USA
  • 15.9. McNeil Consumer Healthcare
  • 15.10. Sun BioPharma

16. Strategic Recommendations

17. About Us & Disclaimer